Cefuroxime Axetil for Otitis Media, Streptococcal Pharyngitis
Cefuroxime axetil is a second-generation cephalosporin antibiotic developed by Glaxo. It is resistant to beta-lactamase.
Cefuroxime is used to treat:
Cefuroxime for Ear Infection
Cefuroxime is officially labeled for the treatment of otitis media (middle ear infection). It is considered a second-line treatment as an alternative to amoxicillin or amoxicillin-clavulanate7. Cefuroxime axetil may be used in patients with Non-type I allergy to penicillin.
Studies in children 3 months to 12 years of age demonstrate that a 10-day course of cefuroxime axetil is as effective or more effective than a 10-day course of cefaclor, amoxicillin, or Augmentin. The overall clinical response rate to cefuroxime axetil in children with AOM ranges from 62–94%4.
Short 5-days regimen of cefuroxime axetil also appears to be effective for the treatment of otitis media in children. In a randomized study in children 3 months to 12 years of age with acute otitis media, a satisfactory bacteriologic response (cure or presumed cure) was obtained in 92% of those who received a 5-day regimen of cefuroxime axetil (30 mg/kg daily given in 2 divided doses), 84% of those who received a 10-day regimen or cefuroxime axetil (30 mg/kg daily given in 2 divided doses), or 95% of those who received a 10-day regimen of Augmentin (40 mg/kg daily given in 3 divided doses).
Cefuroxime axetil 5-day therapy is as effective as Augmentin 8- or 10-day therapy and produces fewer gastrointestinal side effects (diarrhea) in the treatment of acute otitis media in children 6–36 months of age1.
Some doctors caution that short-term antibiotic regimens (5 days or less) may not be appropriate for the treatment of otitis media in children younger than 2 years of age or for those with underlying disease, recurrent or persistent otitis media, or perforated tympanic membranes and spontaneous purulent drainage.
Cefuroxime dosage for Ear Infection
Cefuroxime for Pharyngitis and Tonsillitis (Strep Throat)
Cefuroxime axetil is officially labeled for the treatment of streptococcal pharyngitis and tonsillitis caused by group A beta-hemolytic streptococci.
Cefuroxime is highly effective for the treatment of streptococcal pharyngitis and tonsillitis. In addition, short-course (4–5 day) of cefuroxime axetil also provides successful treatment. In clinical study5 the symptoms improvement rate was 94.8% in children who received the 4-day cefuroxime. 30 days after treatment, the infection relapse rate was only 2.8%.
Cefuroxime is very effective in eradicating chronic streptococcal carriage6.
Cefuroxime dosage for Pharyngitis and Tonsillitis
Mechanism of action
Cefuroxime is a bactericidal beta-lactam antimicrobial. It inhibits the third and final stage of bacterial cell wall synthesis by preferentially binding to specific proteins (PBPs) that are located inside the bacterial cell wall. After antibiotic has bound to these receptors, the transpeptidation reaction is inhibited and peptidoglycan synthesis is blocked. Finally, it results in bacterial lysis.